AbbVievsNeurocrine Biosciences

ABBV and NBIX stock compared: price, dividend, valuation and results, from SEC filings.

NBIX

Neurocrine Biosciences, Inc.

$167.40

Value $16.8B

-1.18%
NBIX's page

AbbVie (ABBV) has a market value of $522B and Neurocrine Biosciences (NBIX) $16.8B. Over the last year, with dividends, ABBV moved +30.3% and NBIX +14.0%. The P/E is 50.7 for ABBV and 23.9 for NBIX. Dividend yield: ABBV 2.35%, NBIX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$522B

    NBIX$16.8B

    ABBV is 31 times NBIX

  • Revenue, 12 months

    ABBV$66.0B

    NBIX$3.7B

    ABBV is 18 times NBIX

  • Net income, 12 months

    ABBV$10.3B

    NBIX$703M

    ABBV is 15 times NBIX

  • Operating margin

    ABBV32.2%

    NBIX24.0%

    8.2 points apart

  • ROIC

    ABBV25.7%

    NBIX19.4%

    6.3 points apart

  • P/E

    ABBV50.7

    NBIX23.9

    ABBV is 2.1 times NBIX

  • Dividend yield

    ABBV2.4%

    NBIX0.0%

    2.4 points apart

  • 5-year return

    ABBV+201.5%

    NBIX+90.2%

    111.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+201.5%

NBIX+90.2%

10020030020222023202420252026
Returns by period
PeriodABBVWith dividendsNBIXWith dividends
1 year since November 12, 2025+30.3%Price +26.5%+14.0%Price +14.0%
3 years since November 13, 2023+135.3%+33.0% a yearPrice +112.8%+51.8%+14.9% a yearPrice +51.8%
5 years since November 12, 2021+201.5%+24.7% a yearPrice +152.2%+90.2%+13.7% a yearPrice +90.2%
10 years since November 15, 2016+605.5%+21.6% a yearPrice +369.3%+216.3%+12.2% a yearPrice +216.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieNBIXNeurocrine Biosciences

Valuation

ABBVNBIX
Valuation
Price$295.03$167.40
Market value$522B$16.8B
Enterprise value (EV)$592B$16.1B
P/E50.723.9
P/E, 5-year median57.053.3
P/B–4.3
EV/EBIT27.918.1
Free cash flow yield3.6%6.2%

Results and growth

ABBVNBIX
Results and growth
Revenue, 12 months$66.0B$3.7B
Net income, 12 months$10.3B$703M
Free cash flow, 12 months$18.9B$1.0B
Earnings per share, 12 months$5.81$6.74
Revenue growth, year on year8.6%21.5%
Revenue growth a year, past+5.9%over 5 years+22.3%over 5 years
EPS growth a year, past-2.8%over 5 years+2.3%over 5 years

Margins and returns on capital

ABBVNBIX
Margins and returns on capital
Gross margin73.7%97.8%
Operating margin32.2%24.0%
Net margin15.7%19.0%
ROIC25.7%19.4%
ROE–20.4%

Balance sheet

ABBVNBIX
Balance sheet
Cash$10.8B$738M
Total debt$80.9B$452M
Net debt / EBITDA3.2-0.8
Interest cover7.1×–

Dividends and buybacks

ABBVNBIX
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%1.0%
Shareholder yield2.5%1.0%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or NBIX

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Neurocrine Biosciences?

By market value, AbbVie ($522B) is about 31.0 times Neurocrine Biosciences ($16.8B), at today's prices.

How did ABBV and NBIX stock do over the last 10 years?

Since November 15, 2016, ABBV's price moved +369.3% and NBIX's +216.3%. With dividends: ABBV +605.5% (+21.6% a year), NBIX +216.3% (+12.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or NBIX?

The dividend yield at today's price is 2.35% for AbbVie and none for Neurocrine Biosciences. Over the last twelve months they paid $6.92 and – per share.

What is the P/E of ABBV and NBIX?

At today's price, the P/E is 50.7 for ABBV and 23.9 for NBIX. The median of the last five years was 57.0 and 53.3, which shows where each stands against its own past.

Which has the higher profit margins, AbbVie or Neurocrine Biosciences?

Over the last twelve months, the net margin was 15.7% for AbbVie and 19.0% for Neurocrine Biosciences, and the operating margin 32.2% and 24.0%. Revenue was $66.0B and $3.7B.

Which is the better investment, AbbVie or Neurocrine Biosciences?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.